Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384.
For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.
对于局限性胰腺癌患者，新辅助治疗（neoadjuvant therapy，NT）越来越多地在手术前进行，以最大限度地提高接受多模式治疗的机会和获得阴性切缘的几率。三十年来，NT 的应用不断完善，已被接受为胰腺腺癌的有效治疗方法。在这篇综述中，我们讨论了 NT 用于胰腺癌患者的原理和最近的全球趋势。
